stars 1 stars 2 stars 3

Oryzon Genomics S.A. is the first Spanish Biomarker and Target Discovery Company with an In-Vitro Diagnostics and Therapeutic R&D pipeline focused in oncology and neurodegenerative diseases.

Crystax Pharmaceuticals / Oryzon Genomics Questions

The Crystax Pharmaceuticals / Oryzon Genomics annual revenue was $9.1 million in 2026.

Tamara Maes is the Founder and Shareholder of Crystax Pharmaceuticals / Oryzon Genomics.

43 people are employed at Crystax Pharmaceuticals / Oryzon Genomics.

Crystax Pharmaceuticals / Oryzon Genomics is based in Cornella de Llobregat, Catalonia.

The NAICS codes for Crystax Pharmaceuticals / Oryzon Genomics are [541711, 54161, 32, 5416, 541612, 54171, 541, 5417, 54, 325].

The SIC codes for Crystax Pharmaceuticals / Oryzon Genomics are [28, 283].

Top Crystax Pharmaceuticals / Oryzon Genomics Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users